Budgets/Spending/Market Size

Move an attempt to address rising costs of country's national pharmacare scheme.

A new study suggests that Ottawa's cuts to the Interim Federal Health Program (IFHP) have led to a rise in admission rates.

Report predicts substantial growth for the systemic psoriasis market.

An Australian researcher says a quirk in that country’s Pharmaceutical Benefits Scheme (PBS) costs the Australian government an extra AUS$120 million (CDN $122 million) each year because the government pays full price for combination medications.